Cargando…
Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors
The aim of this study was to determine the clinical features, treatment factors, and prognosis of patients with multiple primary malignant tumors (MPMTs). In total, 161 patients with MPMTs at our hospital (The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China) were analyz...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413286/ https://www.ncbi.nlm.nih.gov/pubmed/28445321 http://dx.doi.org/10.1097/MD.0000000000006799 |
_version_ | 1783233159644577792 |
---|---|
author | Lv, Meng Zhang, Xiao Shen, Yanwei Wang, Fan Yang, Jiao Wang, Biyuan Chen, Zheling Li, Pan Zhang, Xiaoman Li, Shuting Yang, Jin |
author_facet | Lv, Meng Zhang, Xiao Shen, Yanwei Wang, Fan Yang, Jiao Wang, Biyuan Chen, Zheling Li, Pan Zhang, Xiaoman Li, Shuting Yang, Jin |
author_sort | Lv, Meng |
collection | PubMed |
description | The aim of this study was to determine the clinical features, treatment factors, and prognosis of patients with multiple primary malignant tumors (MPMTs). In total, 161 patients with MPMTs at our hospital (The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China) were analyzed in this study. We found that among 161 patients with MPMTs, 78 (48.4%) patients had synchronous tumors and 83 (51.6%) patients had metachronous tumors. Most clinical and pathological features were similar in both groups. Most patients with MPMTs were men and older patients (>50 years old), and adenocarcinoma was the most frequent pathology type. The most frequent location of all MPMTs was the digestive system. The leading tumor association was between digestive–digestive tumors, also. However, patients with synchronous tumors and MPMTs of the digestive system showed a shorter survival time. In the metachronous cancer group, the median interval time was 60 months, and a short interval time (≤60 months) was associated with a shorter survival time. In addition, survival time was increased in the younger age group (≤50 years old) and in patients who accepted surgery-based comprehensive therapy. However, only interval time (≤60 months) was an independent prognostic factor associated with survival for the metachronous cancer group. Therefore, careful surveillance and follow-up are especially important in these patients. |
format | Online Article Text |
id | pubmed-5413286 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-54132862017-05-05 Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors Lv, Meng Zhang, Xiao Shen, Yanwei Wang, Fan Yang, Jiao Wang, Biyuan Chen, Zheling Li, Pan Zhang, Xiaoman Li, Shuting Yang, Jin Medicine (Baltimore) 4400 The aim of this study was to determine the clinical features, treatment factors, and prognosis of patients with multiple primary malignant tumors (MPMTs). In total, 161 patients with MPMTs at our hospital (The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China) were analyzed in this study. We found that among 161 patients with MPMTs, 78 (48.4%) patients had synchronous tumors and 83 (51.6%) patients had metachronous tumors. Most clinical and pathological features were similar in both groups. Most patients with MPMTs were men and older patients (>50 years old), and adenocarcinoma was the most frequent pathology type. The most frequent location of all MPMTs was the digestive system. The leading tumor association was between digestive–digestive tumors, also. However, patients with synchronous tumors and MPMTs of the digestive system showed a shorter survival time. In the metachronous cancer group, the median interval time was 60 months, and a short interval time (≤60 months) was associated with a shorter survival time. In addition, survival time was increased in the younger age group (≤50 years old) and in patients who accepted surgery-based comprehensive therapy. However, only interval time (≤60 months) was an independent prognostic factor associated with survival for the metachronous cancer group. Therefore, careful surveillance and follow-up are especially important in these patients. Wolters Kluwer Health 2017-04-28 /pmc/articles/PMC5413286/ /pubmed/28445321 http://dx.doi.org/10.1097/MD.0000000000006799 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 4400 Lv, Meng Zhang, Xiao Shen, Yanwei Wang, Fan Yang, Jiao Wang, Biyuan Chen, Zheling Li, Pan Zhang, Xiaoman Li, Shuting Yang, Jin Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors |
title | Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors |
title_full | Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors |
title_fullStr | Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors |
title_full_unstemmed | Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors |
title_short | Clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors |
title_sort | clinical analysis and prognosis of synchronous and metachronous multiple primary malignant tumors |
topic | 4400 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413286/ https://www.ncbi.nlm.nih.gov/pubmed/28445321 http://dx.doi.org/10.1097/MD.0000000000006799 |
work_keys_str_mv | AT lvmeng clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors AT zhangxiao clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors AT shenyanwei clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors AT wangfan clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors AT yangjiao clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors AT wangbiyuan clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors AT chenzheling clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors AT lipan clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors AT zhangxiaoman clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors AT lishuting clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors AT yangjin clinicalanalysisandprognosisofsynchronousandmetachronousmultipleprimarymalignanttumors |